Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive heart disease caused by a buildup of a misfolded protein (TTR) in the heart. Over time, this stiffens the heart and leads to symptoms of heart failure (shortness of breath, fatigue, swelling, etc.). Until now, treatment options have been limited. However, the FDA has approved Amvuttra® (vutrisiran) […]
